Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Completed · Phase 1

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the the dose-response of insulin detemir and insulin NPH in subjects with type 2 diabetes of various race and ethnicity.

Key facts

Study ID

NCT01497600

Run by

Novo Nordisk A/S

People needed

50

Starts

2004-02-01

Expected to finish

2004-08-01

Last updated by the study team

2017-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes
• Insulin treatment with any insulin preparation/regimen for at least three months with or without combination with below or equal to 2 oral antidiabetic agents (OADs)
• Duration of diabetes at least 12 months
• Body Mass Index (BMI) below 33 kg/m\^2
• HbA1c maximum 10 % based on analysis from the central laboratory

You may not qualify if…

• Current treatment with insulin above 1.2 U/kg/day
• Current treatment with drugs known to interfere with glucose metabolism other than OADs such as systemic corticosteroids, non-selective beta-blockers, and monoamino oxidase (MAO) inhibitors
• Blood donation of more than 500 mL within the last three months

Where it is running

• Novo Nordisk Investigational Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.